

1 **Full title:** Identifying Barriers to Disclosure to Overcome Barriers to ART Initiation: An
2 explanatory qualitative study on PMTCT in Zambia

3

4 **Short title:** Partner disclosure and barriers to ART initiation and adherence

5

6 **Authors and affiliations:**

7 Tukiya Kanguya¹ ¶, Aybüke Koyuncu¹¶, Anjali Sharma¹, Thankian Kusanathan², Martha

8 Mubanga¹, Benjamin H. Chi³, Michael J. Vinikoor⁴, Mwangelwa Mubiana-Mbewe¹

9

10 ¹ Centre for Infectious Diseases Research in Zambia, Lusaka, Zambia

11 ² Department of Gender Studies, University of Zambia, Lusaka, Zambia

12 ³ University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of
13 America

14 ⁴ University of Alabama at Birmingham, Birmingham, Alabama, United States of America

15

16 **Corresponding author:**

17 Tukiya Kanguya

18 Email: Tukiya.Kanguya@cidrz.org (TK)

19

20 ¶ These authors contributed equally to this work.

21

22

23 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Abstract**

25 **Background:** Though antiretroviral therapy (ART) is widely available, HIV positive
26 pregnant women in Zambia are less likely to start and remain on therapy throughout
27 pregnancy and after delivery. This study sought to understand readiness to start ART among
28 HIV pregnant women from the perspectives of both women and men in order to suggest more
29 holistic programs to support women to continue life-long ART after delivery.

30

31 **Methods:** We conducted a qualitative study with HIV positive pregnant women before
32 and after ART initiation, and men with female partners, to understand readiness to start
33 lifelong ART. We conducted a total of 28 in-depth interviews among women and 2 focus group
34 discussions among male partners. Data was transcribed verbatim and analyzed in NVivo 12
35 using thematic analysis. Emerging themes from the data were organized using the social
36 ecological framework.

37

38 **Results:** Men thought of their female partners as young and needing their supervision to
39 initiate and stay on ART. Women agreed that disclosure and partner support were necessary
40 preconditions to ART initiation and adherence and expressed fear of divorce as a prominent
41 barrier to disclosure. Maternal love and desire to look after one's children instilled a sense
42 of responsibility among women which motivated them to overcome individual,
43 interpersonal and health system level barriers to initiation and adherence. Women
44 preferred adherence strategies that were discrete, the effectiveness of which, depended on
45 women's intrinsic motivation.

46

47 **Conclusion:** The results support current policies in Zambia to encourage male

48 engagement in ART care. To appeal to male partners, messaging on ART should be centered

49 on emphasizing the importance of male involvement to ensure women remain engaged in

50 ART care. Programs aimed at supporting postpartum ART adherence should design

51 messages that appeal to both men's role in couples' joint decision- making and women's

52 maternal love as motivators for adherence.

53

54 **Introduction**

55 Despite impressive gains towards reaching global goals for ending HIV, Zambia is short

56 of reaching the 95-95-95 UNAIDS target for HIV diagnosis, antiretroviral therapy (ART)

57 initiation and viral suppression in women. In 2017, approximately 72,000 children were

58 living with HIV and 7,300 children become newly infected with HIV [1]. Data from Southern

59 African region have shown that women who initiated ART during pregnancy had a poor 24-

60 month retention in care, and this contributed to an increasing number of children being

61 infected during the breastfeeding period [2]. Approximately 60% of new HIV infections in

62 children occur during the breastfeeding period due to poor maternal ART adherence and

63 inadequate systems of follow-up for postpartum mothers [3]. Therefore, supporting pregnant

64 women to identify and overcome barriers to long-term ART use is a major priority to eliminate

65 PMTCT in the country.

66 Barriers to timely ART initiation among HIV pregnant women vary from the fear of

67 the side effects of the drug, lack of spousal involvement to community stigma [2]. Recent

68 research has shown that that the risk factors for low adherence include being of a younger

69 age, less educated and employed in the informal sector [5]. Selected reported barriers for not
70 being ready to start or continue on ART included physical, economic and emotional stresses,
71 depression (especially after delivery), alcohol or drug use, and ART dosing frequency or pill
72 burden [2,4,5]. While many women overcome these barriers during pregnancy, they may
73 disengage from care after birth.

74 Furthermore, one of the major deterrents to initiation and sustained adherence has
75 been the lack of male involvement in ART care as women need to discuss their HIV status with
76 their husbands before deciding to start ART[6–8]. Men’s attitude to joining Prevention of
77 Mother to Child Transmission (PMTCT) in sub-Saharan Africa has been linked to cultural
78 expectations and the social norm that hold women responsible for attending PMTCT [9]. Men
79 in Botswana regarded antenatal care (ANC) facilities as being "generally unfriendly" to them
80 [10]. Most recently, a review of studies incorporating men suggested that male "support" as
81 well as "involvement" is key to increasing PMTCT uptake [11]. The WHO 2010-2015 guidelines
82 on PMTCT emphasize the need to involve male partners to scale up PMTCT services in sub-
83 Saharan Africa [12]. Despite this, there is limited literature on the perspectives from male
84 partners on reasons women delay to initiate drugs and disengage from care after delivery.

85 The Zambian government adopted the Elimination of Mother-to-Child Transmission
86 of HIV (EMTCT) goal to eliminate new pediatric HIV infections by 2021 which requires that
87 95% of HIV positive pregnant women be on treatment and are retained in care [13]. Achieving
88 this goal will require a deeper understanding of the barriers towards both initiation and
89 retention on ART among HIV positive pregnant women from the perspective of both men and
90 women. To address this knowledge gap, we conducted a formative qualitative research study
91 to better understand readiness to start lifelong ART among HIV-infected pregnant women.

92 The research question underlying this study is therefore, Understanding the readiness to start
93 lifelong ART among HIV-infected pregnant women. The findings from this study will be used
94 to design interventions that encourage both male and female involvement in antenatal care
95 in health facilities in Zambia

96

97 **Methods**

98 **Research setting**

99 This study was conducted in 2 urban health centers in Lusaka District, Zambia,
100 approximately 1 year after introduction of Option B+ in Zambia (i.e., universal and lifelong
101 ART for all pregnant and breastfeeding women living with HIV). Health centers were
102 purposively sampled in consultation with the Lusaka District Health office to include urban
103 government facilities with medium to high patient volume and physical space for study
104 activities at the clinic. Lusaka district is one of four districts within Lusaka Province, which is
105 home to approximately 20% of Zambia's population of 17 million [14]. Most residents in
106 Lusaka District live below the poverty line in high-density peri-urban slums or "compounds"
107 with poor access to safe water and sanitation. Similar to many countries in sub-Saharan
108 Africa, the HIV epidemic disproportionately impacts individuals living in urban areas in Zambia
109 with Lusaka province having the highest prevalence of HIV infection among adults (15.7%)
110 [15].

111 **Study procedures**

112 We utilized formative qualitative research to understand readiness to start lifelong
113 ART among HIV-infected pregnant women. Findings from this research were used to develop

114 and evaluate a quantitative tool to assess ‘readiness’ for ART initiation and an intervention
115 package aimed at supporting adherence and retention on treatment among the pregnant
116 population, for which results are presented elsewhere [16].

117 This project was reviewed in accordance with CDC human research protection
118 procedures and was determined to be research, but CDC investigators did not interact with
119 human subjects or have access to identifiable data or specimens for research purposes.
120 Ethical approval for the study was obtained from the University of Zambia Biomedical
121 Research Ethics Committee (Lusaka, Zambia) and the University of North Carolina at Chapel
122 Hill Institutional Review Board (Chapel Hill, NC, USA).

123

124 **Participants**

125 HIV-infected pregnant women not yet on ART (pre-ART group) and HIV-infected
126 pregnant or postnatal (≤ 42 days after delivery) women on ART (post-ART group) were
127 recruited to participate in in-depth interviews (IDIs). Partners of women who were recently
128 or were currently pregnant were also recruited in the study to participate in focus group
129 discussions (FGDs) in an effort to understand male perspectives on barriers and facilitators of
130 ART initiation and adherence. Male partners may or may not have been the partners of
131 women participating in IDIs, and did not necessarily have partners living with HIV. All
132 participants in the various study groups were 18 years of age or older, did not have a known
133 history of mental illness, were able to communicate in one of the three languages used in the
134 study (English, Nyanja or Bemba) and provided written informed consent to participate in the
135 study. The target sample size needed to reach saturation of themes and patterns emerging

136 from data related to the beliefs, behaviors, and experiences of men and women in each study
137 group was determined prior to sampling and data collection [17,18].

138 Study participants were recruited using convenience sampling. Women presenting at
139 ANC visits or under-5 clinics at the selected urban health centers were sensitized about the
140 study during the daily routine group health talks. Women interested in the study were
141 screened for study participation. In addition, women were identified through their health
142 records, in collaboration with the health facility staff, and all those meeting inclusion criteria
143 were approached on an individual basis for study participation. All eligible women were
144 recruited after providing informed consent. Sensitization about the study for men was done
145 in the general outpatient clinic, TB clinic or ART clinic at the same health facilities. Men were
146 approached individually to establish interest and those interested were screened for study
147 participation. In addition, community sensitization was done through community leaders;
148 men were then approached individually in the community in various places including markets,
149 bus-stops, churches and other public spaces. Those interested in participating were then
150 invited to the study site and screened for study participation. Eligible men were recruited
151 after providing informed consent. Recruiting of men outside the health facilities was done in
152 order to minimize bias towards men with positive health-seeking behavior.

153

154 **Data collection**

155 Data were collected between June and September 2015. Topics shown previously to
156 be important when measuring ART readiness were covered in IDIs, namely: disclosure,
157 partner involvement, psychosocial issues, HIV medication beliefs, and alcohol and drug use
158 [19]. To understand individual barriers and facilitators of ART initiation, we assessed women's

159 knowledge and understanding of ART, their experiences with stigma and discrimination, their
160 existing support structures, and their individual motivations. HIV-infected pregnant women
161 were enrolled and interviewed before or within seven days of ART initiation (pre-ART group)
162 and then a subset of these women was asked to participate in an additional IDI 2-3 months
163 after their first IDI to assess changes in barriers to initiation over time. Participants who had
164 already initiated ART at presentation (post-ART group) were asked about barriers and
165 facilitators to ART adherence, with topics including: social support, distance from clinics and
166 transportation, cultural norms, partner involvement, patient-provider relationships, HIV-
167 related stigma, and experiences at health facilities. Participants were asked to assess the
168 quality and effectiveness of adherence services already received (e.g. adherence counselling);
169 they were also asked for suggestions for additional or alternative services that could be
170 provided to help improve adherence to ART.

171 FGDs with men who currently have female partners who are/were recently pregnant
172 concentrated on their knowledge about HIV and PMTCT, factors that impact starting and
173 adhering to ARVs among pregnant women, and the level of men's engagement in their
174 partner's healthcare during and after pregnancy defined as support in the home or at clinic
175 visits.

176 All IDIs and FGDs were conducted in English or one of two local languages (Nyanja and
177 Bemba) and held in a private setting at one of the two study clinics or the Centre for Infectious
178 Disease Research in Zambia (CIDRZ) research facility in Lusaka, Zambia.

179

180 **Framework**

181 We used the social ecological framework [20] to organize results by sex. The social
182 ecological model is a theory-based framework for understanding the interactive effects of
183 individual, interpersonal, health system level and structural factors on behavior. The insights
184 provided by the model help design multi-faceted behavior change interventions that went
185 beyond the individual. We defined individual level factors as those within a woman's control
186 and awareness; interpersonal level factors as a woman's primary relationships affecting her
187 ART treatment, health system level factors as health care structure and design; and structural
188 level factors as women's socio-economic environment.

189

190 **Analysis**

191 Audio recordings of IDIs and FGDs were transcribed verbatim and translated from local
192 languages of Nyanja and Bemba to English by trained research assistants. Data were analyzed
193 using inductive thematic analysis, which is a comprehensive process involving reading
194 through the transcripts for familiarization and identifying emerging key themes and codes
195 which are then entered into a codebook [21]. The data was subsequently coded by two coders
196 using QSR International's *NVivo* 12 qualitative data analysis software. Coding was compared
197 amongst the two coders for consistency and similarity. Emerging themes for barriers and
198 facilitators of ART initiation and adherence were organized according to levels of the social
199 ecological framework (individual, interpersonal, health system, or structural level
200 barriers/facilitators).

201

202 **Results**

203 **Characteristics of study population**

204 We conducted a total of 28 IDIs among 20 pregnant and postpartum HIV-infected
 205 mothers and 2 FGDs among 16 men in groups of 8. Demographic characteristics of the women
 206 and men are shown in Tables 1 and 2 respectively. Among 20 women, 12 women had IDIs at
 207 only one time-point (5 in pre-ART group, and 7 in post-ART group) and 8 pre-ART women had
 208 a follow-up IDI that took place 2-3 months after their first interview. IDIs that occurred only
 209 at one time-point were conducted among a mix of pregnant (N=7) and postnatal (≤ 42 days
 210 after delivery) (N=5) women.

211 Because immediately ART initiation had become standard of care, at the time of their
 212 first IDI, 17 of 20 mothers (85.0%) had initiated on ART and 1 mother (4.8%) indicated plans
 213 to initiate the day of her interview (Table 1). Only 1 participant who had not initiated ART at
 214 the time of their first IDI had a subsequent follow-up IDI, and initiated ART prior to her follow-
 215 up interview. All participants with follow-up interviews who had initiated ART at the time of
 216 their first IDI (N=7) reported still being on ART at the time of their follow-up interview.

217
 218 **Table 1. Characteristics of pregnant and postnatal HIV-infected women participating in in-**
 219 **depth interviews, Lusaka, Zambia, 2015**
 220

Characteristic	N (%) or Median (IQR)
Age, years	31 (29-37)
Number of children before the current pregnancy	2 (2-4)
Marital status	
Cohabiting/Married	18 (90.0)
Missing	2 (10.0)

Educational level	
Primary	4 (20.0)
Secondary	14 (70.0)
Tertiary	1 (5.0)
Missing	1 (5.0)
Primary occupation	
Not employed or keeps household	11 (55.0)
Formally employed ^A	2 (10.0)
Business woman or self employed	6 (30.0)
Missing	1 (5.0)
Initiated ART at/before IDI	17 (85.0)
Clinic	
Facility 1	9 (45.0)
Facility 2	11 (55.0)

221 ^A Employed in an organization, company, institution, or shop

222

223 **Table 2. Characteristics of Male partners participating in the Focus Group Discussions**
224 **(FGDs) in Lusaka, Zambia, 2015.**

Characteristic	N (%) or Median (IQR)
Total = 16	

Age, years		38 (28-45)
Marital status		
	Cohabiting/Married	16 (100.0)
Primary occupation		
	Not employed or keeps household	2 (12.5)
	Formally employed ^A	6 (37.5)
	Businessman or self employed	6 (37.5)
	Occasionally Employed	1 (6.3)
	Informally Employed	1 (6.3)
Highest Level of Education		
	Primary	1 (6)
	Secondary	10 (63)
	Tertiary	5 (31)
Health Facility ^B		
	Facility 1	8 (50)
	Facility 2	8 (50)

225 ^A Employed in an organization, company, institution, or shop

226 ^B Health facility and corresponding catchment area where recruitment took place

227

228 **Women's perspectives on barriers and facilitators to ART initiation**

229 Pregnant and postnatal women in this study reported a range of barriers to ART
230 initiation within all hierarchies of the social-ecological model (individual, interpersonal, health
231 system, and structural levels). Women who had already initiated ART as well as those who
232 had not yet initiated viewed partner disclosure and partner support of ARVs as necessary for
233 ART initiation. A participant who had not initiated ART at the time of her interview explained:

234

235 *"I always think of how am I going to manage taking ARVs without my partner*
236 *knowing, because definitely he has to know about me being on treatment.*
237 *Since I have never disclosed my status, I feel it is unfair for me to start taking*
238 *ARVs without my partner knowing."* (Female, 31 years, had not initiated ART).

239

240 Barriers to partner disclosure, such as fear of partner blame and fear of divorce, were
241 reported as substantive barriers to ART initiation among both pregnant and postnatal
242 women:

243

244 *"... It's not like I tested HIV positive today, it has been two years. [I have] not*
245 *disclosed my status to him because there are a lot of fear. He might end up*
246 *leaving me ... I think the main challenge that women have is actually disclosure.*
247 *If I go to a clinic and I am tested alone and am HIV positive, what if he asks me*
248 *what made me do it? Maybe he would say that, 'You know what you have been*
249 *doing, that is why you went for a test'; or he may end up accusing me having*
250 *extramarital affairs, that is why I went quiet ... It is very difficult if am tested*

251 *alone for me to go and tell my partner that I tested positive.” (Female, 31 years,*
252 *had not initiated ART).*

253

254 Only 2 participants indicated that they did not have plans to initiate ART at the time
255 of their interview. Both of these women had not disclosed their status to their partner, and
256 suggested couples testing and counselling as strategies to support partner disclosure.
257 Suggestions for the need for couples testing and counselling were further strengthened by
258 descriptions from delayed ART acceptors (those who did not accept ART the day that they
259 tested HIV positive) for the need to go home and discuss with their partner prior to initiating
260 ART:

261

262 *“You know when you have just been told news like you are HIV positive, it is*
263 *always hard to accept. So, I had to sit and discuss with my partner; so time*
264 *passed before we made a decision to start taking ARVs. We finally accepted*
265 *our status, my partner and I then agreed that I start taking ARVs yesterday.”*
266 *(Female, 32 years, on ART).*

267

268 In the presence of partner disclosure and support of ARVs, wanting to protect the
269 health of the baby and love for one’s children were facilitators to acceptance of one’s HIV
270 status and readiness to initiate ART. While women described wanting to be healthy and
271 prolong one’s own life as other important individual-level motivators for ART initiation, for
272 many participants these individual desires had substantial interactive effects with maternal
273 love. A mother’s love for her unborn child was sufficient to overcome not only individual
274 barriers such as lack of acceptance of one’s status, feeling healthy, lack of confidence in ability

275 to follow ARV regimens, and fear of harm/side-effects due to ARVs, but also interpersonal
276 and community level barriers such as fear of stigma and health system barriers such as long
277 queues at clinics. Maternal desires to protect their children uniquely instilled a self-
278 responsibility to overcome other existing barriers to ART initiation:

279

280 *"You find people who say bad things about HIV positive people who take ARVs.*

281 *So, it is up to you to ignore all those bad things people say and continue taking*

282 *ARVs to help yourself. If you take your ARVs you will live long enough to keep*

283 *your children, do not listen to what people say." (Female, 29 years, on ART).*

284

285 **Women's perspectives on barriers and facilitators to ART adherence**

286 All women demonstrated proficiency and understanding regarding how ARVs function
287 within the body and the importance of taking doses at the right time. Most women who had
288 initiated ART at the time of the interview expressed no difficulties taking ARV regimens as
289 prescribed by health care workers and only reported few instances of missing doses. Self-
290 reported good adherence, however, was not attributable to a lack of barriers to ART
291 adherence by the women but rather a self-responsibility to overcome these barriers.

292 When asked about personally experienced or reported barriers to taking ARVs,
293 participants described barriers in all hierarchies of the social-ecological framework. For
294 example, reported individual level barriers included lack of partner disclosure, feeling healthy
295 that belied the need for ARVs, interpersonal and community barriers included difficulties
296 getting permission from work to pick up ARVs and misinformation received from churches,
297 and health system barriers included long queues at the clinic. Despite these barriers, an

298 emergent theme was women’s intrinsic motivation to “be serious” with their ARVs and
299 overcome barriers to adherence. For example, when asked why long queues at a clinic could
300 be a barrier to adherence, one participant explained:

301

302 *“That person may not just be serious about their life because mostly when*
303 *people who are not serious come to the clinic for appointments and find that*
304 *there are a lot of people in the queue they will go back. Mostly such people are*
305 *drunkards and not just serious about their lives, that is what causes them to*
306 *stop. But if you really want to have a good and healthy life, you can still wait*
307 *and get your medication.” (Female, 23 years, on ART)*

308

309 Similar to ART initiation, partner support, and the desire to continue taking care of
310 one’s children and watching them grow were seen as significant motivators for adherence to
311 ART. Strategies suggested by participants to support adherence included partner and family
312 reminders, putting ARVs somewhere in the home you can always see them, and always
313 carrying drugs on one’s person. When asked which one strategy would be best for supporting
314 adherence, even after interviewer suggestions for methods such as follow up by peer
315 educators, SMS reminders, adherence counselling, and material incentives, setting alarms on
316 one’s phone or watch was said to be the best strategy for ART adherence. Alarms were
317 described by participants as an effective strategy for supporting adherence that did not
318 jeopardize confidentiality of one’s HIV status and could thus be utilized both by individuals
319 who had and had not disclosed their HIV status to their partners and peers:

320

321 *“The alarm is the most important thing and if you are scared that people will*
322 *ask when it rings, you can put it on vibration. The phone is the most effective*
323 *way for remembering to take ARVs.” (Female, 23 years, on ART).*

324

325 Women had diverse opinions on adherence support strategies listed by the
326 interviewer. Some women believed the strategies could be helpful and others believed the
327 strategies would be ineffective or could unintentionally disclose one’s status to partners or
328 community members (SMS reminders and follow-up by peer educators). The opinion that
329 strategies would be ineffective were based on the belief that adherence had to be intrinsically
330 motivated as explained by one participant:

331

332 *“It [incentives] may look as if someone is begging you to live when this is about*
333 *your life and you just need to encourage yourself.” (Female, unknown age, had*
334 *not initiated ART).*

335

336 **Male partner perspectives on barriers and facilitators to ART**

337 **initiation among women**

338 Men were very knowledgeable and had a common understanding about HIV care and
339 PMTCT in pregnant women. This knowledge ranged from understanding the need for
340 antenatal care visits, recommended diet while on ART and type of medication that women
341 were supposed to take.

342

343 Similar to the women, men reported a range of barriers to ART initiation among the
344 women within hierarchies of the social-ecological model (individual, interpersonal, health
345 system, and structural levels). They highlighted individual barriers to ART initiation such as
346 fear of ARV side effects, self-stigma and spiritual beliefs. However, both men and women
347 agreed that women found it most difficult to overcome individual (e.g., denial) and
348 interpersonal barriers (e.g. fear of divorce or HIV-serodiscordance) to ART initiation and
349 continuation.

350

351 **Fear of divorce**

352 Similar to the women’s perspectives, men thought that fear of divorce or spousal
353 separation impeded ART initiation among married women. Both women and men highly
354 valued and guarded their marital relationship. Having a healthy and positive relationship with
355 their spouse superseded individual physical health. Men repeatedly reported that women
356 were afraid of the marital repercussions of telling them their status and as a result would not
357 take ARVs:

358 *“They fear being divorced and also fear the rejection by families.” (Male, 39 years)*

359

360 *“Another thing is the fear of being divorced. They may say that if I have not
361 disclosed to my husband and start taking ARVs without him knowing, the
362 marriage will come to the end. So mostly they want to protect their marriage,
363 they do not want to be divorced and this is why they do not feel ready to start
364 taking their drugs.” (Male, 29 years)*

365

366 **Discordant relationships**

367 Most of the HIV negative men in discordant relationships reported that their female
368 partners suffered emotional distress. Women in discordant relationships viewed themselves
369 as being marginalized and struggled with understanding how they acquired HIV despite being
370 faithful; these feelings delayed their acceptance of ART. One man thought that women may
371 feel more emotionally supported if their partner was HIV positive:

372 *“On the other hand, I still feel psychologically that she would have preferred it*
373 *if both of us were HIV positive and taking drugs because she feels marginalized.*
374 *[Our sero-discordant status] is something that even I have failed to understand,*
375 *it’s just God’s doing. I have no words to ask why and why not because God*
376 *himself knows better.” (Male, 22 years)*

377

378 **Preference for antenatal HIV testing**

379 In Zambia, the HIV testing available options are routine provider-initiated testing (STI,
380 antenatal and TB clinics), Voluntary Counselling and Testing, Community Based (door to door,
381 mobile outreach) and diagnostic testing. Many men reported that women preferred testing
382 for HIV in antenatal clinics rather than in ART clinics because they thought of them as more
383 private and comfortable. Majority of the men reported that their partners tested for HIV at
384 antenatal visits, preventing them from HIV testing as a couple. Because the men were initially
385 not aware of their partner’s status it was difficult for them to be involved in the health care
386 of partner and also to provide support.

387

388 *“They don’t want to have their HIV test done at voluntary counselling and*
389 *testing (VCT) so that they know if they are positive or negative but they prefer*

390 *it done at antenatal. It's like that's where they feel comfortable." (Male, 39*
391 *years)*

392 *"Women don't want to go for VCT so the best thing to do is to accompany*
393 *them." (Male, 29 years)*

394

395 **Male partner perspectives on barriers and facilitators to ART**

396 **adherence among women**

397 Similar to initiation, men reported facilitators to adherence at both individual and
398 interpersonal level of the social ecological framework. Men reported that strengthening
399 facilitators at individual and interpersonal level improved adherence among the women. At
400 the individual level, men suggested alarm reminders and at the interpersonal level, partner
401 supervision and support from immediate family as facilitators to adherence.

402

403 **Alarm reminders**

404 Similar to the findings from the women, men perceived alarm reminders as helpful in
405 improving adherence among pregnant women. The men reported that they would set alarms
406 on their phones to remind their partners to take medication. Having a fixed time set for taking
407 medication as a couple improved ART uptake among the women:

408

409 *"On the other hand you have to put a reminder on the phone; an alarm which*
410 *when it rings, reminds you to take your drugs." (Male, 21 years)*

411

412 **Paternalistic supervision**

413 According to the men, women needed to be guided by them and take ART under
414 supervision, saying that, “men were the lions and women the sheep”. They reported that men
415 led women to start and remain on ARVs because women went through a phase of constant
416 denial of their HIV diagnosis.

417

418 *“Women also behaves like children. If you give them medicine, some hide them*
419 *under the pillow or even throw them away and sometimes they complain that*
420 *from the time they started taking the same medicine they have never seen any*
421 *change. So monitoring is required.” (Male, 32 years)*

422

423 **Immediate family support**

424 At the interpersonal level, the involvement of the family/household in the uptake of
425 medication helped improve adherence to ART by HIV positive women. Members of the family
426 that were knowledgeable/aware of the status of the women would physically remind them
427 to take their medication. Men believed they were the first source of support in helping to
428 improve adherence, followed by children in the household.

429

430 *“The strategies -- firstly it is disclosure, upon disclosing to your husband or*
431 *children, they need know what time you will be taking the drugs so that they*
432 *can remind you in case you forget” (Male, 21 years)*

433

434 *“There are also psychological reminders like if you have a daughter, you may*
435 *not disclose to her the status of her mother but just tell her that your mother*
436 *will be taking BP medication and you should be reminding her every day. You*
437 *even tell her that this is the responsibility that I have given you and maybe even*
438 *give her a certain amount of money for lunch at school. That is just a*
439 *psychological way but wherever she is she will be reminded that she has to*
440 *remind her mother to take her medication.” (Male, 22 years)*

441

442 **Discussion**

443 Our study identified partner disclosure as a critical facilitator for maternal ART
444 initiation among Lusaka participants. The presence of partner disclosure and support at the
445 interpersonal level was seen as sufficient to overcome all other self-reported socio-ecological
446 barriers to ART initiation. While both women and men also identified male partners as
447 facilitators of ART adherence, they valued different types of support. Men emphasized
448 constant supervision and leadership to ensure women adhere to ART. Women, on the other
449 hand, emphasized the need for open and non-punitive interactions. These results add to
450 research in other low and middle-income countries (LMIC) offering a more nuanced
451 understanding of partner support to help guide appropriate messaging to increase uptake of
452 Option B+.

453 Lack of male knowledge on HIV and PMTCT has previously been identified in numerous
454 studies in sub-Saharan Africa as a barrier to male involvement in PMTCT, partner disclosure,
455 and women’s ART initiation and adherence [22–26]. The high knowledge levels on HIV,
456 PMTCT, and benefits of ARVs among men in our study simultaneously underscore reach of

457 PMTCT promotion but also the inadequacy of the messaging in tailoring male involvement to
458 the expressed needs of their HIV positive pregnant and breastfeeding partners. Our results
459 suggest that interventions aimed at addressing barriers to disclosure, initiation, and
460 adherence could benefit from appealing to the value both men and women place on their
461 relationship as a strategy to increase male involvement in joint decision-making for women's
462 HIV care. Our findings utilize data from 2015, therefore barriers and facilitators for ART
463 initiation and adherence among pregnant and postpartum women may have subsequently
464 changed. Reaching the last 5-10% of women in PMTCT elimination goals will require creative
465 strategies. However, interventions targeting the barriers identified in this analysis have not
466 been widespread. Innovative methods focused on the recruitment of men as pioneers in
467 women's ART initiation and adherence may still be a relevant and necessary strategy for
468 addressing fear of divorce and partner blame as barriers among women who have not yet
469 initiated ART, decreasing delayed acceptance of ART, and supporting ART adherence among
470 pregnant and postpartum women.

471 Our results complement existing literature identifying partner disclosure and support
472 as consistently important facilitators of ART initiation among pregnant women [22–30], but
473 are the first to suggest disclosure/support are both necessary and sufficient to overcome all
474 other self-reported barriers to initiation when coupled with a mother's love for her children.
475 While participants in our study acknowledged similar barriers to ART initiation identified by
476 existing research in sub-Saharan Africa such as community stigma and feeling healthy, in the
477 presence of partner support, participants reported both self-efficacy and responsibility to
478 overcome these barriers mediated by their love for their children. The narrative of self-
479 efficacy in overcoming barriers to ART initiation and adherence was also reflected in the

480 selection of phone-based alarms by both women and men in our study as an effective method
481 for supporting ART adherence.

482 Contrary to previous research conducted among people living with HIV (PLHIV) in
483 Zambia in 2010-11, dissatisfaction with HIV counselling and misinformation about
484 PMTCT/ARVs were not prominent barriers to ART initiation among women in our study
485 population [31]. These findings may be suggestive of improvements to community
486 sensitization and HIV counselling efforts in Zambia. The scale up of HIV care services and ARV
487 delivery in Zambia is further reflected by contrasting the lack of prominent structural level
488 barriers to ART initiation by pregnant mothers in our study to the views of PLHIV in Lusaka in
489 2010 who reported fear of long-term availability of treatment as a significant barrier to ART
490 initiation [31].

491 Our finding that love for one's children and desire to have healthy HIV-free babies
492 were the main motivators for ART initiation and adherence is consistent with existing
493 research [22,24,25,28,30]. However, existing concerns that maternal love may have less
494 influence on ART adherence if the baby is HIV-negative at birth and/or after the breastfeeding
495 period were not supported in our study [23]. Our findings suggest that women may continue
496 on ART in order to live long healthy lives and to take care of their children and watch them
497 grow.

498 Our ability to draw conclusions regarding the strength of a mother's love for her
499 children as a long-term facilitator of ART adherence are limited given that women enrolled in
500 our study were either currently pregnant or ≤ 42 days postpartum at the time of their IDI;
501 however, most of the women already had other children at the time of the interview. Our
502 findings may also have limited generalizability given that women could only be recruited for
503 our study if already attending ANC/under-5 clinics and exhibiting positive health seeking

504 behavior related to their child's health. Our study's reliance on self-reported adherence may
505 also limit our ability to identify barriers to ART adherence due to social desirability bias and
506 women's unwillingness to admit poor adherence, which may have contributed to the low
507 prevalence of self-reported poor adherence in our study. Findings from similar qualitative
508 research among HIV-infected pregnant women in sub-Saharan Africa have identified
509 heterogeneity in self-reported adherence, suggesting that challenges with ART adherence
510 may still be identified in the context of self-report [28]. Despite this, prospective follow-up
511 with HIV-infected mothers after the breastfeeding period with more rigorous measurement
512 of ART adherence is needed to confirm the findings of this study. Additional research is also
513 needed to confirm the findings of this analysis given that our results may have limited
514 generalizability to rural areas though increasing migration of rural populations into urban
515 cities in the last decade may increase the relevance of our findings to rural areas in Lusaka
516 and sub-Saharan Africa [32,33].

517 **Conclusion**

518 While women reported barriers to ART initiation and adherence at all four levels of
519 the social-ecological framework, interventions at the health systems level and structural level
520 may have limited capabilities to facilitate ART initiation and adherence if they do not also
521 address interpersonal barriers related to partner disclosure and support. In order to realize
522 Zambia's ambitious pediatric HIV elimination goals, PMTCT programs need to strongly
523 promote male engagement and utilize behavioral interventions that address the real and
524 perceived negative consequences of HIV status disclosure. Designing messaging that appeal
525 to men's role in couples' joint decision-making for household healthcare and to women's
526 maternal love may motivate women to continue on ART after delivery.

527

528 **Acknowledgements**

529 The authors thank the study participants and the Centre for Infectious Disease
530 Research in Zambia (CIDRZ) staff for their important contributions.

531

532 **References**

- 533 1. Joint United Nations Programme on HIV/AIDS (UNAIDS), UNAIDS D. Programme on HIV.
534 AIDS. 2018; 2018:376p. Available from:
535 https://www.unaids.org/sites/default/files/media_asset/unaid-data-2018_en.pdf
536
- 537 2. Knettel BA, Cichowitz C, Ngocho JS, Knippler ET, Chumba LN, Mmbaga BT, Watt MH.
538 Retention in HIV care during pregnancy and the postpartum period in the Option B+
539 era: a systematic review and meta-analysis of studies in Africa. *Journal of acquired*
540 *immune deficiency syndromes (1999)*. 2018 Apr 15;77(5):427.
541 doi:10.1097/QAI.0000000000001616
542
- 543 3. UNAIDS. 2015 Progress Report on the Global Plan towards the elimination of new HIV
544 infections among children and keeping their mothers alive. 2015. Available:
545 [https://www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport_](https://www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport_GlobalPlan_en.pdf)
546 [GlobalPlan_en.pdf](https://www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport_GlobalPlan_en.pdf)
- 547 4. Minja L, Cichowitz C, Knettel BA, Mahande MJ, Kisigo G, Knippler ET, Ngocho JS,
548 Mmbaga BT, Watt MH. Attitudes Toward Long-Term Use of Antiretroviral Therapy
549 Among HIV-Infected Pregnant Women in Moshi, Tanzania: A Longitudinal Study. *AIDS*
550 *and Behavior*. 2019 Sep 1;23(9):2610-7. doi.org/10.1007/s10461-019-02622-5
- 551 5. Kiwanuka G, Kiwanuka N, Muneza F, Nabirye J, Oporia F, Odikro MA, et al. Retention of
552 HIV infected pregnant and breastfeeding women on option B+ in Gomba District,
553 Uganda: a retrospective cohort study. *BMC Infectious Diseases*. 2018;18: 533.
554 doi:10.1186/s12879-018-3450-9
- 555 6. Hershov RB, Zimba CC, Mweemba O, Chibwe KF, Phanga T, Dunda W, Matenga T,
556 Mutale W, Chi BH, Rosenberg NE, Maman S. Perspectives on HIV partner notification,
557 partner HIV self-testing and partner home-based HIV testing by pregnant and
558 postpartum women in antenatal settings: a qualitative analysis in Malawi and Zambia.
559 *Journal of the International AIDS Society*. 2019 Jul;22:e25293.
560 doi.org/10.1002/jia2.25293
561

- 562 7. Orne-Gliemann J, Tchendjou PT, Miric M, Gadgil M, Butsashvili M, Eboko F, Perez-Then
563 E, Darak S, Kulkarni S, Kamkamidze G, Balestre E. Couple-oriented prenatal HIV
564 counseling for HIV primary prevention: an acceptability study. *BMC public health*. 2010
565 Dec 1;10(1):197. doi.org/10.1186/1471-2458-10-197
566
- 567 8. Theuring S, Mbezi P, Luvanda H, Jordan-Harder B, Kunz A, Harms G. Male involvement
568 in PMTCT services in Mbeya Region, Tanzania. *AIDS Behav*. 2009;13 Suppl 1: 92–102.
569 doi:10.1007/s10461-009-9543-0
- 570 9. Morfaw F, Mbuagbaw L, Thabane L, Rodrigues C, Wunderlich A-P, Nana P, et al. Male
571 involvement in prevention programs of mother to child transmission of HIV: a systematic
572 review to identify barriers and facilitators. *Syst Rev*. 2013;2: 5. doi:10.1186/2046-4053-
573 2-5
- 574 10. Auvinen J, Suominen T, Välimäki M. Male participation and prevention of human
575 immunodeficiency virus (HIV) mother-to-child transmission in Africa. *Psychol Health*
576 *Med*. 2010;15: 288–313. doi:10.1080/13548501003615290
- 577• 11. Takah NF, Atem JA, Aminde LN, Malisheni M, Murewenhema G. The impact of approaches
578 in improving male partner involvement in the prevention of mother-to-child transmission of
579 HIV on the uptake of safe infant feeding practices by HIV positive women in sub-Saharan
580 Africa. A systematic review and meta-analysis. *PloS one*. 2018 Dec 3;13(12):e0207060.
581 doi.org/10.1371/journal.pone.0207060
- 582 12. Millennium Development Goals, United Nations, General Assembly, Special Session,
583 World Health Organization. PMTCT strategic vision 2010-2015: preventing mother-to-
584 child transmission of HIV to reach the UNGASS and Millennium Development Goals :
585 moving towards the elimination of paediatric HIV. Geneva: World health organization;
586 2010. Available: http://www.who.int/hiv/pub/mtct/strategic_vision.pdf
- 587 13. The Republic of Zambia Ministry of Health. Elimination of Mother-to-Child Transmission
588 of HIV and Syphilis National Operational Plan 2019-2021. Available:
589 [https://www.moh.gov.zm/wp-content/uploads/filebase/Elimination-of-Mother-To-
590 Child-Transmission-of-HIV-and-Syphilis-National-Operation-Plan-2019-2021.pdf](https://www.moh.gov.zm/wp-content/uploads/filebase/Elimination-of-Mother-To-Child-Transmission-of-HIV-and-Syphilis-National-Operation-Plan-2019-2021.pdf)
- 591 14. Lusaka (Province, Zambia) - Population Statistics, Charts, Map and Location. [cited 14
592 Oct 2019]. Available: [https://www.citypopulation.de/php/zambia-
593 admin.php?adm1id=05](https://www.citypopulation.de/php/zambia-admin.php?adm1id=05)
- 594 15. Ministry of Health, Zambia. Zambia Population-based HIV Impact Assessment
595 (ZAMPHIA) 2016: Final Report. Lusaka, Ministry of Health. 2019 Feb.
- 596 16. Mubiana-Mbewe M, Bosomprah S, Kadota JL, Koyuncu A, Kusanathan T, Mweebo K, et
597 al. Effect of Enhanced Adherence Package on Early Retention in Care Among HIV-Positive
598 Pregnant Women in Zambia: An Individual Randomized Controlled Trial. Rochester, NY:
599 Social Science Research Network; 2019 Oct. Report No.: ID 3467001. Available:
600 <https://papers.ssrn.com/abstract=3467001>

- 601 17. LeCompte MD, Schensul JJ. Designing & conducting ethnographic research. Walnut
602 Creek, Calif: AltaMira Press; 1999.
- 603 18. Krueger RA, Casey MA. Focus groups: a practical guide for applied research. 4th ed. Los
604 Angeles: SAGE; 2009.
- 605 19. Development of an Easy to Use Tool to Assess HIV Treatment Readiness in Adolescent
606 Clinical Care Settings. [cited 23 Nov 2019]. Available:
607 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203751/>
- 608 20. Golden SD, Earp JAL. Social ecological approaches to individuals and their contexts:
609 twenty years of health education & behavior health promotion interventions. *Health*
610 *Educ Behav.* 2012;39: 364–372. doi:10.1177/1090198111418634
- 611 21. Nowell LS, Norris JM, White DE, Moules NJ. Thematic Analysis: Striving to Meet the
612 Trustworthiness Criteria. *International Journal of Qualitative Methods.* 2017;16:
613 1609406917733847. doi:10.1177/1609406917733847
- 614 22. Hodgson I, Plummer ML, Konopka SN, Colvin CJ, Jonas E, Albertini J, et al. A Systematic
615 Review of Individual and Contextual Factors Affecting ART Initiation, Adherence, and
616 Retention for HIV-Infected Pregnant and Postpartum Women. *PLoS One.* 2014;9.
617 doi:10.1371/journal.pone.0111421
- 618 23. Chadambuka A, Katirayi L, Muchedzi A, Tumbare E, Musarandega R, Mahomva AI, et al.
619 Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding
620 women (Option B+) in selected health facilities in Zimbabwe: a qualitative study. *BMC*
621 *Public Health.* 2017;18. doi:10.1186/s12889-017-4611-2
- 622 24. Kim MH, Zhou A, Mazenga A, Ahmed S, Markham C, Zomba G, et al. Why Did I Stop?
623 Barriers and Facilitators to Uptake and Adherence to ART in Option B+ HIV Care in
624 Lilongwe, Malawi. *PLoS One.* 2016;11. doi:10.1371/journal.pone.0149527
- 625 25. Elwell K. Facilitators and barriers to treatment adherence within PMTCT programs in
626 Malawi. *AIDS Care.* 2016;28: 971–975. doi:10.1080/09540121.2016.1153586
- 627 26. Naigino R, Makumbi F, Mukose A, Buregyeya E, Arinaitwe J, Musinguzi J, Wanyenze RK.
628 HIV status disclosure and associated outcomes among pregnant women enrolled in
629 antiretroviral therapy in Uganda: a mixed methods study. *Reproductive Health.* 2017 Dec
630 1;14(1):107.doi.org/10.1186/s12978-017-0367-5
- 631
- 632 27. Katirayi L, Namadingo H, Phiri M, Bobrow EA, Ahimbisibwe A, Berhan AY, et al. HIV-
633 positive pregnant and postpartum women’s perspectives about Option B+ in Malawi: a
634 qualitative study. *J Int AIDS Soc.* 2016;19. doi:10.7448/IAS.19.1.20919
- 635 28. Buregyeya E, Naigino R, Mukose A, Makumbi F, Esiru G, Arinaitwe J, et al. Facilitators and
636 barriers to uptake and adherence to lifelong antiretroviral therapy among HIV infected
637 pregnant women in Uganda: a qualitative study. *BMC Pregnancy Childbirth.* 2017;17.
638 doi:10.1186/s12884-017-1276-x

- 639 29. Gill MM, Umutoni A, Hoffman HJ, Ndatimana D, Ndayisaba GF, Kibitenga S, et al.
640 Understanding Antiretroviral Treatment Adherence Among HIV-Positive Women at Four
641 Postpartum Time Intervals: Qualitative Results from the Kabeho Study in Rwanda. *AIDS*
642 *Patient Care and STDs*. 2017;31: 153–166. doi:10.1089/apc.2016.0234
- 643 30. Patel RC, Odoyo J, Anand K, Stanford-Moore G, Wakhungu I, Bukusi EA, et al. Facilitators
644 and Barriers of Antiretroviral Therapy Initiation among HIV Discordant Couples in Kenya:
645 Qualitative Insights from a Pre-Exposure Prophylaxis Implementation Study. *PLOS ONE*.
646 2016;11: e0168057. doi:10.1371/journal.pone.0168057
- 647 31. Musheke M, Bond V, Merten S. Deterrents to HIV-patient initiation of antiretroviral
648 therapy in urban Lusaka, Zambia: a qualitative study. *AIDS Patient Care STDS*. 2013;27:
649 231–241. doi:10.1089/apc.2012.0341
- 650 32. Hommann K, Lall SV. Which Way to Livable and Productive Cities?: A Road Map for Sub-
651 Saharan Africa. The World Bank; 2019. doi:10.1596/978-1-4648-1405-1
- 652 33. The World Bank. Republic of Zambia Systematic Country Diagnostic. 2018 Mar. Report
653 No.: 124032-ZM.

654

655

656